Novel Immunotherapeutic Approaches in Head and Neck Cancer.

ABSTRACT: Unresectable recurrent or metastatic head and neck cancer is an incurable disease with survival of approximately 12 months. Head and neck tumors exhibit numerous derangements in the tumor microenvironment that aid in immune evasion and may serve as targets for future therapies. Pembrolizumab is now approved as a first line therapy. Despite the promise of currently approved immunotherapies there continues to be low response rates and additional strategies are needed. Here, alterations in the immune microenvironment and current therapeutic strategies are reviewed with a focus on novel immunologic approaches.

SUBMITTER: Heft Neal ME 

PROVIDER: S-EPMC7357897 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature